Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +65

AlTi Global Inc. Decreases Stake in Abbott Laboratories $ABT

AI-generated analysis

📉 AlTi Global Inc. decreased its Abbott Laboratories stake by 54.7%, reducing holdings from 23,342 shares to 10,563 shares.

📈 Canada Pension Plan Investment Board increased its position by 25.6%, adding 292,547 shares valued at $195.267 million.

💰 Abbott Laboratories reported Q2 EPS of $1.31, beating the consensus estimate of $1.28.

📊 Revenue for the quarter reached $12.51 billion, marking a 13% increase compared to the prior year.

🎯 Analysts set an average price target of $118.61 with a general 'Moderate Buy' consensus rating.

💵 The company declared a quarterly dividend of $0.63 per share, yielding 2.5% annually.

👔 CFO Philip P. Boudreau purchased 2,200 shares at an average price of $91.50.

🏛️ Director Daniel J. Starks acquired 10,000 shares for a total value of $926,500.

📅 Q3 2026 EPS guidance is set between $1.38 and $1.46 per share.

🏥 Abbott operates globally through diagnostics, medical devices, nutritionals, and pharmaceuticals.

Bullish Signals
  • Abbott Laboratories beat quarterly earnings expectations with EPS of $1.31 versus the consensus of $1.28.
  • The company achieved a 13% year-over-year revenue increase, reporting $12.51 billion in quarterly sales.
  • Major institutional investor Canada Pension Plan Investment Board increased its stake by 25.6%.
  • CFO Philip P. Boudreau and Director Daniel J. Starks recently purchased shares, signaling insider confidence.
  • Analysts maintain an average price target of $118.61, which is above the current trading price.
  • The company provided solid forward guidance for Q3 2026 EPS between $1.38 and $1.46.
Risk Factors
  • AlTi Global Inc. significantly reduced its position in Abbott Laboratories by 54.7% during the first quarter.
  • Jefferies Financial Group lowered its price objective from $145.00 to $135.00, though maintaining a 'buy' rating.
  • Sanford C. Bernstein reduced its price target from $125.00 to $110.00 while keeping an 'outperform' rating.
Full Analysis
AlTi Global Inc. significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 54.7% in the first quarter, selling 12,779 shares to hold a remaining position of 10,563 shares valued at $1.085 million. This move contrasts with several other institutional investors who increased their holdings during the same period. Brighton Jones LLC added 4,755 shares, while major entities like the Canada Pension Plan Investment Board boosted their positions by 25.6%, acquiring an additional 292,547 shares valued at $195.267 million. Abbott Laboratories recently reported strong quarterly financial results, beating analyst expectations with earnings per share of $1.31 against a consensus of $1.28 and revenue of $12.51 billion, which represented a 13% year-over-year increase. The company also provided forward guidance for Q3 2026 EPS between $1.38 and $1.46 and full-year 2026 EPS between $5.45 and $5.60. Analysts maintain a generally positive outlook, with an average price target of $118.61 and ratings ranging from Strong Buy to Hold. Corporate insiders have also demonstrated confidence in the company's prospects through recent stock purchases. CFO Philip P. Boudreau acquired 2,200 shares at an average cost of $91.50, while Director Daniel J. Starks purchased 10,000 shares for a total transaction value of $926,500. The company recently declared a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record as of July 15th, reflecting an annualized yield of 2.5%.